Logo

PMCB

PharmaCyte Biotech, Inc.

PMCB

PharmaCyte Biotech, Inc. • NASDAQ
$0.77 ▼ -6.33% (-0.05)
Market Cap $5.24 M
52w High $1.90
52w Low $0.63
Dividend Yield 0%
P/E 12.86
Volume 557.34K
Outstanding Shares 6.80M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q1-2026 $0 $848.305K ▼ $-8.36M ▼ 0% $-1.23 ▼ $-8.36M ▼
Q4-2025 $0 $1.042M ▲ $11.75M ▲ 0% $1.6 ▲ $-1.042M ▼
Q3-2025 $0 $960.252K ▼ $-3.045M ▼ 0% $-0.44 ▼ $-960K ▲
Q2-2025 $0 $1.106M ▼ $-1.47M ▼ 0% $-0.39 ▼ $-1.106M ▼
Q1-2025 $0 $1.269M $23.421M 0% $1.9 $0

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2026 $13.44M ▼ $45.11M ▼ $1.519M ▼ $43.592M ▼
Q4-2025 $15.538M ▼ $55.168M ▲ $3.277M ▼ $51.891M ▲
Q3-2025 $16.756M ▼ $43.829M ▼ $3.578M ▼ $40.25M ▼
Q2-2025 $20.84M ▼ $55.098M ▼ $11.647M ▼ $43.451M ▼
Q1-2025 $32.635M $70.194M $17.153M $53.041M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2026 $-8.36M ▼ $-1.994M ▼ $0 $0 ▲ $-1.994M ▼ $-1.994M ▼
Q4-2025 $11.75M ▲ $-1.04M ▼ $0 $-171.543K ▲ $-1.211M ▲ $-1.04M ▼
Q3-2025 $-3.045M ▼ $-509.893K ▲ $0 ▼ $-3.945M ▲ $-4.457M ▲ $-509.893K ▲
Q2-2025 $-1.47M ▼ $-1.055M ▼ $7M ▲ $-10.74M ▼ $-11.795M ▲ $-1.055M ▼
Q1-2025 $23.421M $-373.297K $-7M $-10.172M $-17.545M $-373.297K

Five-Year Company Overview

Income Statement

Income Statement Income statement PharmaCyte is still a pre‑revenue biotech: it has not generated product or licensing revenue in recent years. Historically, the company has reported losses tied mainly to R&D, corporate overhead, and public-company costs. A recent small accounting profit appears more like a one‑off or result of cost cutting and financial items rather than evidence of a stable, profitable business model. In practical terms, the core operations remain loss‑making and dependent on outside funding until a product is approved or a partnership generates income.

Balance Sheet

Balance Sheet Balance sheet The balance sheet is very small and thin. The company holds only a modest amount of total assets, mostly cash and equivalents, with essentially no traditional debt, which reduces interest burden but also signals limited scale. Equity is positive but not large, meaning the financial cushion to absorb ongoing losses is quite modest. Given the company’s stage and history of reverse splits, future growth or even simple continuation of operations is likely to depend on raising additional capital, which could dilute existing shareholders.

Cash Flow

Cash Flow Cash flow Cash flow from operations is effectively zero in the summarized data, consistent with a company that has no revenue and tightly controlled spending. Capital expenditures are minimal, reflecting an asset‑light, research‑oriented model rather than heavy investment in facilities. In practice, the real cash story is simple: the business relies on its cash balance and any future capital raises to fund R&D and overhead. With spending already curtailed and no operating inflows, the key question going forward is how quickly remaining cash is used and whether new funding can be secured on acceptable terms.

Competitive Edge

Competitive Edge Competitive position PharmaCyte’s competitive edge comes from its specialized Cell‑in‑a‑Box live‑cell encapsulation platform, protected by patents and orphan drug status for its pancreatic cancer program. The approach—locally activating chemotherapy at the tumor—differs from traditional systemic treatments and offers a clear scientific rationale. However, the competitive position is fragile. The lead pancreatic cancer program has been under an FDA clinical hold for several years, freezing its main path to validation. In diabetes and other cell‑therapy areas, the company faces much larger, better funded rivals, including big biotechs working on encapsulated cell devices. Without clinical momentum, partnerships, or a clear strategic focus, its moat is more theoretical than proven in the marketplace.

Innovation and R&D

Innovation and R&D Innovation & R&D The company’s core innovation is the Cell‑in‑a‑Box encapsulation technology, designed to create “bio‑artificial organs” that can activate drugs or produce hormones inside the body. This is scientifically ambitious and highly differentiated, with potential applications in pancreatic cancer, malignant ascites, cannabinoid‑based cancer treatments, and previously diabetes. R&D momentum, however, appears constrained. The FDA hold on the pancreatic cancer program has forced extra preclinical and manufacturing work, delaying human trials. Management has also decided to stop pursuing the diabetes program, and overall spending has been scaled back pending strategic review. The pipeline is therefore early‑stage, capital‑intensive, and dependent on regulatory progress and future funding before any of these innovations can translate into commercial products.

Summary

Summary PharmaCyte Biotech is a very small, pre‑revenue biotechnology company built around a distinctive cell‑encapsulation platform with potentially broad medical applications. On paper, its technology and patent estate offer interesting scientific upside, especially in difficult cancers like pancreatic cancer. Financially, the company operates with a thin balance sheet, no meaningful revenue, and an ongoing need for external financing. The long‑standing FDA clinical hold on its lead program, the scaling back of R&D, and the decision to drop the diabetes effort all increase execution risk and cast uncertainty on the long‑term strategy. Overall, PMCB represents an early‑stage, high‑risk biotech story where future outcomes hinge on resolving regulatory issues, clarifying strategic direction, and maintaining access to capital, more than on current financial performance.

NEWS

November 25, 2025 · 9:15 AM UTC

PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment

Read more